BiotechTube

YM443

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dyspepsia

Conditions

Dyspepsia, Functional Dyspepsia

Trial Timeline

Aug 1, 2008 → Dec 1, 2009

NCT ID
NCT00764374

About YM443

YM443 is a phase 3 stage product being developed by Astellas Pharma for Dyspepsia. The current trial status is completed. This product is registered under clinical trial identifier NCT00764374. Target conditions include Dyspepsia, Functional Dyspepsia.

What happened to similar drugs?

3 of 15 similar drugs in Dyspepsia were approved

Approved (3) Terminated (3) Active (11)
🔄Cinitapride + domperidoneEisaiPhase 3
🔄Z-338Zeria PharmaceuticalPhase 3
🔄Imonogas + EspumisanJohnson & JohnsonPhase 3
✅esomeprazoleAstraZenecaApproved
✅Esomeprazole MagnesiumAstraZenecaApproved
🔄TegaserodNovartisPhase 3
🔄TegaserodNovartisPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00764374Phase 3Completed
NCT00102310Phase 2Completed

Competing Products

20 competing products in Dyspepsia

See all competitors
ProductCompanyStageHype Score
YH12852 0.1 mg + YH12852 0.25 mg + YH12852 0.5 mg + PlaceboYuhanPhase 2
27
YM443 + Placebo + MoxifloxacinAstellas PharmaPhase 1
29
Cinitapride + domperidoneEisaiPhase 3
40
Rabeprazole + Rabeprazole + Rabeprazole + PlaceboEisaiPhase 2
35
Z-338Zeria PharmaceuticalPhase 3
40
Imonogas + EspumisanJohnson & JohnsonPhase 3
40
esomeprazoleAstraZenecaApproved
43
Esomeprazole MagnesiumAstraZenecaApproved
35
TegaserodNovartisPhase 3
40
TegaserodNovartisPhase 3
40
TegaserodNovartisPhase 3
40
Tegaserod and PlaceboNovartisApproved
35
TegaserodNovartisPhase 3
40
TegaserodNovartisPhase 3
40
Gabapentin + PlaceboPfizerPhase 3
32
Z-338Zeria PharmaceuticalPhase 2
35
Z-338Zeria PharmaceuticalPhase 2
35
Z-338Zeria PharmaceuticalPhase 2
35
Z-338 + PlaceboZeria PharmaceuticalPhase 3
40
Acotiamide hydrochloride hydrate + PlaceboZeria PharmaceuticalPhase 3
44